Intrahepatic cholangiocarcinoma

This phase 2 trial tests an experimental drug called XmAb20717 in 27 adults with advanced biliary tract cancers (bile duct or gallbladder cancer) that worsened after standard chemotherapy. The drug is a bispecific antibody designed to activate the immune system against cancer by …

This study tests a two-pronged chemotherapy approach for people with intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be removed by surgery. Participants receive chemotherapy directly to the liver through a surgically placed pump, plus standard chemotherap…

This Phase 2 trial tested a combination of three treatments—local chemotherapy delivered via beads into the liver, a targeted drug called apatinib, and an immunotherapy (PD-1 antibody)—in 20 patients with advanced bile duct cancer that had worsened after standard first-line chemo…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…

This phase 2 study tested a combination of two drugs, durvalumab and SNDX-6352, in 5 people with advanced bile duct cancer that had not spread beyond the liver. Participants first received standard chemo or radiation therapy directly into the liver, then the drug combination. The…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …

This early-phase trial tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, cartilage cancer, and brain tumors) that have a specific IDH1 mutation. The study first found a safe dose, then expanded to see how well the drug works. …

This phase III trial tested whether adding nab-paclitaxel to the standard two-drug chemo (gemcitabine and cisplatin) helps people with newly diagnosed, advanced biliary tract cancers live longer. Over 450 patients took part. The goal is to see if the three-drug combo improves ove…

This phase 2 trial tested a combination of three drugs—chemotherapy delivered directly to the liver, a targeted pill, and an immunotherapy—in 25 people with advanced bile duct cancer that could not be removed surgically. The goal was to see if the combination could shrink tumors …

This study tested whether adding a liver-directed chemotherapy infusion (HAIC) to a standard drug combo (Gemox, lenvatinib, toripalimab) helps people with advanced bile duct cancer live longer without the disease getting worse. 96 patients took part. The goal was to see if the ex…

This phase 2 trial tested a new chemotherapy combination (Nal-IRI with 5-FU and leucovorin) against a standard treatment (gemcitabine plus cisplatin) in 93 people with advanced biliary tract cancer that could not be removed by surgery. The study aimed to see which approach better…

This study tested a drug called ZW25 (zanidatamab) in 87 people with advanced or metastatic HER2-amplified biliary tract cancer that had worsened after standard chemotherapy. The goal was to see if the drug could shrink tumors and how long that effect lasted. The trial is now com…

This study tested proton beam radiation, a highly targeted form of radiotherapy, in 83 people with liver cancer that could not be surgically removed. The goal was to see if this precise approach could control tumors while reducing damage to healthy tissue. Participants received d…

This phase 2 trial tested colchicine, a drug usually used for gout, in 42 people with advanced liver cancer that could not be treated with curative intent. Participants took colchicine tablets daily in cycles of 4 days on, 3 days off. The study measured how long patients survived…

This completed study tested a new blood test that looks for tiny particles called exosomal microRNAs to detect intrahepatic cholangiocarcinoma, a rare and aggressive liver cancer. Researchers analyzed blood samples from 535 adults to see how accurately the test could identify can…

This study tested a new blood test called LyMIC that looks for tiny particles (exosomes) released by cancer cells. The goal was to see if it could accurately tell whether bile duct cancer has spread to nearby lymph nodes before surgery. Researchers analyzed blood samples from 230…

This large completed trial tested whether an AI system can help radiologists better diagnose liver tumors from CT scans. Over 10,000 adults with various liver conditions participated. The AI analyzed scans overnight, and a senior radiologist reviewed any differences between the A…

This study looked at whether a special ultrasound using gas microbubbles can predict how well bile duct cancer responds to targeted radiotherapy. The ultrasound can also pop these bubbles, which might make the cancer easier to treat. Sixteen adults with bile duct cancer took part…

This completed study looked at 3000 patients having liver surgery to see if considering both medical and social factors could reduce how long they stay in the hospital. Researchers tracked things like complications and readmissions. The goal is to find ways to improve recovery an…

This study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue r…

This completed study looked at 169 patients with a type of liver cancer called intrahepatic cholangiocarcinoma. Researchers used MRI scans and machine learning to measure scar tissue and a protein linked to tumor growth. The goal was to see if these features could predict how lon…

This study tested whether a blood test that looks at tiny particles called exosomes can find cancer that has spread but is not visible on scans in people with a type of bile duct cancer (intrahepatic cholangiocarcinoma). The goal was to help doctors know who needs stronger treatm…

This completed study used artificial intelligence to examine CT scans from 274 liver cancer patients who had already received radiation therapy. The goal was to find the radiation dose that causes a visible liver reaction, which could help doctors avoid liver injury in future tre…